Literature DB >> 24360118

Intercellular adhesion molecule-1 mediates murine colon adenocarcinoma invasion.

Kenton Howard1, Karen K Lo1, Lihua Ao1, Fabia Gamboni1, Barish H Edil1, Richard Schulick1, Carlton C Barnett2.   

Abstract

BACKGROUND: Intercellular adhesion molecule-1 (ICAM-1) modulates cell-cell adhesion and is a receptor for cognate ligands on leukocytes. Upregulation of ICAM-1 has been demonstrated in malignant transformation of adenomas and is associated with poor prognosis for many malignancies. ICAM-1 is upregulated on the invasive front of pancreatic metastases and melanomas. These data suggest that the upregulated ICAM-1 expression promotes malignant progression. We hypothesize that the downregulation of ICAM-1 will mitigate tumor progression.
METHODS: Mouse colon adenocarcinoma cells (MC38) were evaluated for the expression of ICAM-1 using Western immunoblot analysis. Short hairpin RNA (shRNA) transduction was used to downregulate ICAM-1. Tumor invasion determined via a modified Boyden chamber was used as a surrogate of tumor progression examining MC38 cells, MC38 ICAM-1 knockdowns, and MC38 transduced with vehicle control. The cells were cultured in full media for 24 h and serum-starved for 24 h. A total of 5 × 10(4) cells were plated and allowed to migrate for 24 h using full media with 10% fetal bovine serum as a chemoattractant. Inserts were fixed and stained with crystal violet. Blinded investigators counted the cells using a stereomicroscope. Statistical analysis was performed by analysis of variance with Fischer protected least significant difference and a P value of <0.05 was considered statistically significant.
RESULTS: ICAM-1 was constitutively expressed on MC38 cells. Transduction with anti-ICAM-1 shRNA vector downregulated ICAM-1 protein expression by 30% according to the Western blot analysis (P < 0.03) and decreased ICAM-1 messenger RNA expression by 70% according to the reverse transcription-polymerase chain reaction. shRNA knockdown cells had a significant reduction in invasion >45% (P < 0.03). There were no significant differences between the invasion rates of MC38 and MC38 vehicle controls.
CONCLUSIONS: Downregulation of ICAM-1 mitigates MC38 invasion. These data suggest that targeted downregulation of tumor ICAM-1 is a potential therapeutic target.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alpha-actinin; Extracellular matrix; Intercellular adhesion-molecule 1; Macrophage; Neutrophil

Mesh:

Substances:

Year:  2013        PMID: 24360118      PMCID: PMC4844553          DOI: 10.1016/j.jss.2013.11.001

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  14 in total

1.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

Authors:  D Hanahan; G Bergers; E Bergsland
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

2.  Preferential sites for stationary adhesion of neutrophils to cytokine-stimulated HUVEC under flow conditions.

Authors:  P K Gopalan; A R Burns; S I Simon; S Sparks; L V McIntire; C W Smith
Journal:  J Leukoc Biol       Date:  2000-07       Impact factor: 4.962

3.  Activation state of stromal inflammatory cells in murine metastatic pancreatic adenocarcinoma.

Authors:  Douglas D Benson; Xianzhong Meng; David A Fullerton; Ernest E Moore; Joon H Lee; Lihua Ao; Christopher C Silliman; Carlton C Barnett
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-03-14       Impact factor: 3.619

4.  Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts.

Authors:  Christina L Roland; Sean P Dineen; Jason E Toombs; Juliet G Carbon; C Wayne Smith; Rolf A Brekken; Carlton C Barnett
Journal:  Exp Biol Med (Maywood)       Date:  2010-02

5.  Immune regulation of cancer.

Authors:  Mary L Disis
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

6.  The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma.

Authors:  Gail M Gauvreau; Allan B Becker; Louis-Philippe Boulet; Jamila Chakir; Robert B Fick; William L Greene; Kieran J Killian; Paul M O'byrne; John K Reid; Donald W Cockcroft
Journal:  J Allergy Clin Immunol       Date:  2003-08       Impact factor: 10.793

7.  ICAM-1-CD18 interaction mediates neutrophil cytotoxicity through protease release.

Authors:  C C Barnett; E E Moore; G W Mierau; D A Partrick; W L Biffl; D J Elzi; C C Silliman
Journal:  Am J Physiol       Date:  1998-06

8.  ICAM-1 expression determines malignant potential of cancer.

Authors:  Christina L Roland; Alden H Harken; Michael G Sarr; Carlton C Barnett
Journal:  Surgery       Date:  2007-06       Impact factor: 3.982

9.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

10.  Association of intercellular adhesion molecule-1 (ICAM-1) with actin-containing cytoskeleton and alpha-actinin.

Authors:  O Carpén; P Pallai; D E Staunton; T A Springer
Journal:  J Cell Biol       Date:  1992-09       Impact factor: 10.539

View more
  8 in total

1.  Tissue necrosis and its role in cancer progression.

Authors:  Adi Karsch-Bluman; Ariel Feiglin; Eliran Arbib; Tal Stern; Hila Shoval; Ouri Schwob; Michael Berger; Ofra Benny
Journal:  Oncogene       Date:  2018-11-02       Impact factor: 9.867

2.  Dose-response Effects of Aerobic Exercise Among Colon Cancer Survivors: A Randomized Phase II Trial.

Authors:  Justin C Brown; Andrea B Troxel; Bonnie Ky; Nevena Damjanov; Babette S Zemel; Michael R Rickels; Andrew D Rhim; Anil K Rustgi; Kerry S Courneya; Kathryn H Schmitz
Journal:  Clin Colorectal Cancer       Date:  2017-06-17       Impact factor: 4.481

3.  DNA copy number alterations, gene expression changes and disease-free survival in patients with colorectal cancer: a 10 year follow-up.

Authors:  Elisabetta Bigagli; Carlotta De Filippo; Cinzia Castagnini; Simona Toti; Francesco Acquadro; Francesco Giudici; Marilena Fazi; Piero Dolara; Luca Messerini; Francesco Tonelli; Cristina Luceri
Journal:  Cell Oncol (Dordr)       Date:  2016-10-05       Impact factor: 6.730

4.  Dextran sulfate prevents excess aggregation of human pluripotent stem cells in 3D culture by inhibiting ICAM1 expression coupled with down-regulating E-cadherin through activating the Wnt signaling pathway.

Authors:  Haibin Wu; Xianglian Tang; Yiyu Wang; Ning Wang; Qicong Chen; Jinghe Xie; Shoupei Liu; Zhiyong Zhong; Yaqi Qiu; Ping Situ; Mark A Zern; Jue Wang; Honglin Chen; Yuyou Duan
Journal:  Stem Cell Res Ther       Date:  2022-05-26       Impact factor: 8.079

5.  A randomized phase II dose-response exercise trial among colon cancer survivors: Purpose, study design, methods, and recruitment results.

Authors:  Justin C Brown; Andrea B Troxel; Bonnie Ky; Nevena Damjanov; Babette S Zemel; Michael R Rickels; Andrew D Rhim; Anil K Rustgi; Kerry S Courneya; Kathryn H Schmitz
Journal:  Contemp Clin Trials       Date:  2016-03-10       Impact factor: 2.226

Review 6.  Bioactive nanotherapeutic trends to combat triple negative breast cancer.

Authors:  Pallabita Chowdhury; Upasana Ghosh; Kamalika Samanta; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu
Journal:  Bioact Mater       Date:  2021-03-13

7.  Effects of exercise on circulating tumor cells among patients with resected stage I-III colon cancer.

Authors:  Justin C Brown; Andrew D Rhim; Sara L Manning; Luke Brennan; Alexandra I Mansour; Anil K Rustgi; Nevena Damjanov; Andrea B Troxel; Michael R Rickels; Bonnie Ky; Babette S Zemel; Kerry S Courneya; Kathryn H Schmitz
Journal:  PLoS One       Date:  2018-10-17       Impact factor: 3.240

8.  Hepatic thermal injury promotes colorectal cancer engraftment in C57/black 6 mice.

Authors:  Alison L Halpern; J Gregory Fitz; Yuki Fujiwara; Jeniann Yi; Aimee L Anderson; Yuwen Zhu; Richard D Schulick; Karim C El Kasmi; Carlton C Barnett
Journal:  Am J Physiol Cell Physiol       Date:  2020-11-11       Impact factor: 4.249

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.